Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
OS Therapies Incorporated - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
OSTX
NYSE American
2834
ostherapies.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for OS Therapies Incorporated
OS Therapies Provides Corporate Update
- Feb 4th, 2025 12:33 pm
RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis
- Feb 3rd, 2025 1:30 pm
OS Therapies to acquire listeria programs from Ayala Pharmaceuticals
- Jan 30th, 2025 2:35 pm
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
- Jan 29th, 2025 3:05 pm
OS Therapies price target raised to $15 from $8 at Maxim
- Jan 17th, 2025 1:35 pm
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
- Jan 15th, 2025 2:17 pm
OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2025 4:16 pm
OS Therapies Announces Closing of $6 Million Private Placement
- Dec 31st, 2024 8:38 pm
OS Therapies Partners With B2i Digital to Engage With Biotech Investors Online
- Dec 26th, 2024 5:04 pm
OS Therapies to sell 1.5M units at $4.00 in private placement
- Dec 25th, 2024 2:40 pm
OS Therapies Announces Pricing of $6 Million Private Placement
- Dec 24th, 2024 2:32 pm
OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
- Nov 15th, 2024 2:47 pm
OS Therapies to Present at The Spartan Capital Investor Conference
- Nov 4th, 2024 12:00 pm
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
- Oct 30th, 2024 12:51 pm
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
- Oct 28th, 2024 8:44 pm
OS Therapies to Present at the LD Micro Main Event XVII
- Oct 24th, 2024 12:46 pm
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- Oct 17th, 2024 1:22 pm
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
- Oct 3rd, 2024 12:00 pm
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
- Sep 13th, 2024 12:09 pm
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
- Sep 11th, 2024 12:15 pm
Scroll